Clinical trials: Asthma
Asthma
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved…
- Trial name
- NCT06502366
- Testing
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg
- Where
- 128 sites in United States, China and 4 more
- Volunteers
- 424 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma
The goal of this clinical trial is to evaluate whether two different doses of an investigational drug (CP006 Inhalation Powder, a triple combination of budesonide, formoterol, and umeclidinium) improve lung function in adults…
- Trial name
- CP006-ASTHMA (NCT07807007)
- Testing
- Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Albuterol Sulfate
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Moderate-to-Severe Asthma
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.
- Trial name
- PRESENT (NCT06422663)
- Where
- 31 sites in China
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
The goal of this study is to learn if a new formulation of Budesonide/Formoterol Inhalation Powder (160μg/4.5μg), manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd., works the same as the already approved reference…
- Trial name
- BF-BE (NCT07804303)
- Testing
- Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test), Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Severe Asthma
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
- Trial name
- TAPER (NCT07363642)
- Testing
- Tezepelumab
- Where
- 75 sites in China
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Safety in Asthma Patients
Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
This is a phase 1 study, randomized, double-blind, placebo-controlled, 2 treatment, 2 period crossover study to evaluate the pharmacokinetics, safety, and tolerability of a single inhaled dose of ASY202 in adults with stable…
- Trial name
- NCT07665892
- Testing
- ASY202
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aspeya, Inc.
Asthma, Bronchial
A Non-interventional, Prospective Study With Benralizumab
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients…
- Trial name
- AIR POWER (NCT06422078)
- Where
- 41 sites in Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Severe Asthma
Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia
ELBRUS is a 12-month (52-week), multi-centre, prospective, non-comparative and non-interventional (observational), post-reimbursement real-world evidence study that will assess patient-reported outcomes after tezepelumab…
- Trial name
- ELBRUS (NCT06566885)
- Where
- 15 sites in Russia
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Asthma
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years…
- Trial name
- MITCHELL (NCT06644924)
- Testing
- Intervention: AS MDI, Intervention: Ventolin Evohaler
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Asthma
Budesonide/Formoterol Inhalation Powder in Adults With Asthma
The goal of this clinical trial is to evaluate whether budesonide/formoterol powder for inhalation (II) manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd.
- Trial name
- BF-ASTHMA (NCT07790159)
- Testing
- Budesonide and Formoterol Fumarate
- Where
- 28 sites in China
- Volunteers
- 338 people
- Sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Asthma
Self-Management Of Asthma By Forced Oscillation Technique
Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing and responding to deterioration in control with effective treatments can improve asthma…
- Trial name
- PIANOFORTE (NCT04963140)
- Testing
- Optimized self-management of asthma, Conventional self-management of asthma
- Where
- 9 sites in Australia, France and 1 more
- Volunteers
- 39 people
- Sponsor
- Restech Srl
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Asthma
Tezepelumab PRO Study
This study assesses the impact of tezepelumab treatment not only on asthma control but also on cough specific Health-Related Quality of Life (HRQoL). Asthma control can be evaluated using Asthma Control Questionnaire (ACQ).
- Trial name
- TezepelumabPRO (NCT05922891)
- Where
- 29 sites in Japan
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo.
- Trial name
- NCT05222529
- Testing
- Glycopyrronium bromide 25ug, Glycopyrronium bromide 12.5ug
- Where
- 23 sites in Bulgaria, Colombia and 6 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately…
- Trial name
- NCT06829784
- Testing
- TQC2731 injection
- Where
- 101 sites in China
- Volunteers
- 660 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Asthma
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of…
- Trial name
- NCT06419413
- Where
- 21 sites in China
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
- Trial name
- MODIFY (NCT07456033)
- Testing
- Depemokimab
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 456 people
- Sponsor
- GlaxoSmithKline
Asthma (Diagnosis)
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with…
- Trial name
- NCT07768891
- Testing
- Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER®
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.